The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers.


Journal

European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373

Informations de publication

Date de publication:
11 2021
Historique:
received: 16 07 2021
accepted: 28 07 2021
pubmed: 25 9 2021
medline: 29 10 2021
entrez: 24 9 2021
Statut: ppublish

Résumé

Europe is an important focus for compiling accurate and up-to-date world cancer statistics owing to its large share of the world's total cancer burden. This article presents incidence and mortality estimates for 25 major cancers across 40 individual countries within European areas and the European Union (EU-27) for the year 2020. The estimated national incidence and mortality rates are based on statistical methodology previously applied and verified using the most recently collected incidence data from 151 population-based cancer registries, mortality data and 2020 population estimates. Estimates reveal 4 million new cases of cancer (excluding non-melanoma skin cancer) and 1.9 million cancer-related deaths. The most common cancers are: breast in women (530,000 cases), colorectum (520,000), lung (480,000) and prostate (470,000). These four cancers account for half the overall cancer burden in Europe. The most common causes of cancer deaths are: lung (380,000), colorectal (250,000), breast (140,000) and pancreatic (130,000) cancers. In EU-27, the estimated new cancer cases are approximately 1.4 million in males and 1.2 million in females, with over 710,000 estimated cancer deaths in males and 560,000 in females. The 2020 estimates provide a basis for establishing priorities in cancer-control measures across Europe. The long-established role of cancer registries in cancer surveillance and the evaluation of cancer control measures remain fundamental in formulating and adapting national cancer plans and pan-European health policies. Given the estimates are built on recorded data prior to the onset of coronavirus disease 2019 (COVID-19), they do not take into account the impact of the pandemic.

Identifiants

pubmed: 34560371
pii: S0959-8049(21)00497-4
doi: 10.1016/j.ejca.2021.07.039
pmc: PMC8568058
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

308-347

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest statement None declared.

Références

Acta Oncol. 2021 Jan;60(1):20-23
pubmed: 33287604
Int J Cancer. 2010 Mar 15;126(6):1454-66
pubmed: 19728330
Stat Med. 2000 Jul 15;19(13):1741-52
pubmed: 10861775
Eur J Cancer Prev. 2017 Sep;26(5):447-452
pubmed: 26919133
Eur J Cancer. 1990;26(11-12):1167-256
pubmed: 2150000
Br J Cancer. 2018 Apr;118(8):1130-1141
pubmed: 29567982
Eur J Cancer. 2018 May;94:6-15
pubmed: 29502036
Ann Oncol. 2007 Mar;18(3):581-92
pubmed: 17287242
Eur J Cancer. 2002 Jan;38(1):99-166
pubmed: 11750846
Eur J Cancer. 2020 Apr;129:41-49
pubmed: 32120274
Radiol Oncol. 2020 Jul 29;54(3):329-334
pubmed: 32726291
Int J Cancer. 2007 Mar 15;120(6):1336-43
pubmed: 17192897
Eur J Cancer. 2015 Jun;51(9):1144-63
pubmed: 24269041
Lancet Oncol. 2020 Jun;21(6):750-751
pubmed: 32359403
Eur J Public Health. 2022 Apr 1;32(2):311-315
pubmed: 34935934
Eur J Cancer. 2010 Mar;46(4):765-81
pubmed: 20116997
Breast. 2017 Dec;36:89-95
pubmed: 28988610
Eur J Cancer. 2010 Nov;46(17):3040-52
pubmed: 21047585
Ann Intern Med. 1998 Jun 1;128(11):900-5
pubmed: 9634428
Stat Med. 1994 Aug 15;13(15):1513-23
pubmed: 7973230
Eur J Cancer. 2018 Nov;103:356-387
pubmed: 30100160
Ann Oncol. 2005 Mar;16(3):481-8
pubmed: 15718248
Ann Oncol. 2020 May;31(5):650-658
pubmed: 32321669
N Engl J Med. 2018 May 03;378(18):1734-1740
pubmed: 29580179
Eur J Cancer. 1997 Jun;33(7):1075-107
pubmed: 9376190
Bull World Health Organ. 2016 Mar 1;94(3):174-84
pubmed: 26966328
Eur J Cancer. 2015 Jun;51(9):1164-87
pubmed: 24120180
Ann Intern Med. 2018 Jan 16;168(2):143-144
pubmed: 29297002
Eur Urol. 2020 Jan;77(1):38-52
pubmed: 31493960
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Ann Oncol. 2021 Apr;32(4):478-487
pubmed: 33626377
Eur J Cancer. 2008 Feb;44(3):448-53
pubmed: 18083022
Eur J Cancer. 2004 Dec;40(18):2794-803
pubmed: 15571963
Eur J Cancer. 2015 Jun;51(9):997-1017
pubmed: 25956208
Gastroenterology. 2021 May;160(6):2169-2171.e1
pubmed: 33513406
Lancet Oncol. 2014 Jan;15(1):23-34
pubmed: 24314615
Eur J Cancer. 2013 Apr;49(6):1374-403
pubmed: 23485231
Int J Cancer. 2017 Dec 1;141(11):2228-2242
pubmed: 28795403
Lancet Gastroenterol Hepatol. 2019 Dec;4(12):934-947
pubmed: 31648972

Auteurs

Tadeusz Dyba (T)

European Commission, Joint Research Centre (JRC), Ispra, Italy. Electronic address: tadek.dyba@ec.europa.eu.

Giorgia Randi (G)

European Commission, Joint Research Centre (JRC), Ispra, Italy. Electronic address: giorgia.randi@ec.europa.eu.

Freddie Bray (F)

Cancer Surveillance Branch, International Agency for Research on Cancer (IARC), Lyon, France.

Carmen Martos (C)

European Commission, Joint Research Centre (JRC), Ispra, Italy.

Francesco Giusti (F)

European Commission, Joint Research Centre (JRC), Ispra, Italy.

Nicholas Nicholson (N)

European Commission, Joint Research Centre (JRC), Ispra, Italy.

Anna Gavin (A)

Northern Ireland Cancer Registry, Belfast, United Kingdom.

Manuela Flego (M)

European Commission, Joint Research Centre (JRC), Ispra, Italy.

Luciana Neamtiu (L)

European Commission, Joint Research Centre (JRC), Ispra, Italy.

Nadya Dimitrova (N)

European Commission, Joint Research Centre (JRC), Ispra, Italy.

Raquel Negrão Carvalho (R)

European Commission, Joint Research Centre (JRC), Ispra, Italy.

Jacques Ferlay (J)

Cancer Surveillance Branch, International Agency for Research on Cancer (IARC), Lyon, France.

Manola Bettio (M)

European Commission, Joint Research Centre (JRC), Ispra, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH